细胞因子诱导的杀伤细胞联合化疗治疗晚期结肠癌的随机对照研究

A randomized study of cytokine-induced killer cells combined with chemotherapy for advanced colorectal cancer

目的探讨细胞因子诱导的杀伤(cytokine induced killer,CIK)细胞联合FOLFOX4方案化疗治疗晚期结肠癌的临床疗效。方法将85例晚期结肠癌患者进行随机分组:治疗组43例,给予FOLFOX4方案化疗+CIK细胞治疗;对照组42例,给予FOLFOX4方案化疗。比较两组患者的免疫功能、生活质量、近期疗效、远期生存率及不良反应。结果经过治疗后,治疗组CD3+、CD4+、CD4+/CD8+比值及CD16+CD56+显著上升,CD8+细胞显著下降,与治疗前相比差异有统计学意义(P<0.05);对照组CD3+、CD4+、CD8+、CD4+/CD8+及CD16+CD56+与治疗前相比差异无统计学意义(P>0.05)。治疗组QOL评分改善83.7%,明显高于对照组的33.3%(P<0.001)。治疗组客观有效率为67.4%,对照组为61.9%,两组比较差异无统计学意义(P=0.593)。治疗组和对照组的1年、2年生存率分别为93.0%vs 83.3%,81.4%vs 69.0%,两组比较差异无统计学意义(P=0.166,P=0.187)。治疗组和对照组的不良反应无显著差异(P>0.05)。结论 CIK细胞联合化疗可以提高晚期结肠癌患者的免疫功能,改善生活质量。

Objective To observe the clinical efficacy of cytokine- induced killer cells（CIK） combined with FOLFOX4 regimen chemotherapy for advanced colorectal cancer. Method A total of 85 patients with advanced colorectal cancer were randomized into treatment group or control group. In treatment group, 43 patients received FOLFOX4 chemotherapy ＋ CIK cell therapy; while in control group, 42 patients were administered with FOLFOX4 chemotherapy. The immune function, quality of life, short-term effect, long-term survival and adverse reactions of the two groups were analyzed. Result After treatment, the levels of CD3^＋, CD4^＋, CD4^＋/CD8^＋ratio and CD16^＋CD56^＋were increased and the CD8^＋was decreased significantly（P〈0.05） in the treatment group, and those measures in the control group showed no significant changes（P〉0.05）. Quality of life of 83.7% patients in the treatment group was improved, which was significantly higher than the 33.3% in the control group（P〈0.001）. The objective response rates（ORR） in treatment group and control group were 67.4% vs 61.9%, of which the difference was not significant（P= 0.593）. The 1-year and 2-year survival rate in treatment group and control group were 93.0% vs 83.3%,81.4% vs 69.0%, and there were no statistically significant differences between two groups（P= 0.166, P= 0.187）. Also, the side effects in the both groups were similar（P〉0.05）. Conclusion CIK cells combined with chemotherapy in the treament of advanced colorectal cancer can improve patients＇ immune function and quality of life.